Gb Sciences’ innovative approach harnesses the power of plant-based treatments as simplified mixtures that target dangerous hyperinflammatory responses to viral infections.

As mental health disorders increasingly impact global populations, Gb Sciences is developing psychotropic but non-psychedelic treatments for anxiety and depression that compete with the emerging billion-dollar psychedelic companies.

As published in the journal Food and Chemical Toxicology, the biopharmaceutical drug development firm’s sponsored research used co-cultured human, primary immune cells as a model to evaluate the ability of selected Cannabis constituents to decrease inflammation.

At the Annual Summit, Dr. Andrea Small-Howard is presenting a Keynote Address that includes data from case studies demonstrating the utility of Gb Sciences’ proprietary PhAROS drug discovery platform.

Gb Sciences’ anxiety formulations were previously identified using the company’s AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the National Research Council of Canada.

Dr. Andrea Small-Howard discusses the company’s novel process for developing disease-specific, cannabinoid-based therapeutics.

As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm’s sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) for the treatment of Parkinson’s disease symptoms

Gb Sciences is focusing considerable resources on bringing its lead Parkinson’s disease formulations to the clinic with promising results; plus, new data validating the efficacy of their novel anxiety formulations and demonstrating the improved stability of their oral nanoparticle-encapsulated chronic pain formulations add value to their drug development pipeline.

President and Chief Science Officer Dr. Andrea Small-Howard demonstrates the platform’s utility for predicting novel plant-inspired drug candidates and describes its role in Gb Sciences’ future successes.

As digitization becomes a necessity in the life sciences industry, Gb Sciences proves it’s already ahead of the curve with its own revolutionary technology.